More evidence for further minimisation of breast-cancer surgery
Mené sur 931 patientes atteintes d'un cancer du sein avec micrométastases au niveau du ganglion sentinelle et traitées par mastectomie ou chirurgie conservatrice (durée médiane de suivi : 9,7 ans), cet essai international de phase III évalue, en fonction de la charge tumorale des ganglions sentinelles, la non infériorité, du point de vue de la survie sans maladie, et la sécurité d'un traitement ne comportant pas de curage ganglionnaire axillaire par rapport à un traitement qui en comporte
Innovations in breast cancer management derive from continuing incremental multidisciplinary progress and integration of any advances to achieve an improvement of patient outcomes greater than the sum of individual improvements. Up to the early 2000s, almost all women throughout the world presenting with clinically node-negative invasive breast cancer routinely received complete axillary lymph node dissection, which can be associated with high morbidity due to lymphoedema, shoulder dysfunction, and pain. The development of the sentinel lymph node biopsy for breast cancer using a radiocolloid lymphatic tracer and blue dyes occurred in the mid-1990s. 1
, 2 Now, this innovative and quality-of-life changing minimised procedure has mostly eliminated the necessity of axillary lymph node dissection globally when the sentinel lymph nodes show minimal disease. It took several prospective single centre and multicentre national and international trials to get to this point. 3, 4
The Lancet Oncology , commentaire, 2017